Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACAL: Oral Recombinant Salmon Calcitonin in Postmenopausal Osteoporosis
NCT00959764Phase 3Completed
- Sponsor
- Tarsa Therapeutics, Inc.
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of calcitonin salmon in osteoporosis (3 arms), sponsored by Tarsa Therapeutics, Inc. Primary endpoint: Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine at 48 weeks. Started Jun 2009; status: completed.
02
Drugs
calcitonin salmon
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00959764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00959764.